Song Siliang, Li Wen, Liang Wenjuan, Tian Xiu
Department of Imaging, Qingdao Hospital of Traditional Chinese Medicine, Qingdao Hiser Hospital, Qingdao 266033, Shandong, China.
Department of Radiotherapy, Qingdao Hospital of Traditional Chinese Medicine, Qingdao Hiser Hospital, Qingdao 266033, Shandong, China.
Evid Based Complement Alternat Med. 2021 Oct 25;2021:8106974. doi: 10.1155/2021/8106974. eCollection 2021.
To explore the clinical efficacy of traditional Chinese medicine decoction combined with recombinant human interferon 2b in the treatment of renal cell carcinoma (RCC).
68 RCC patients were divided into the control group and treatment group ( = 34). The control group was treated with recombinant human interferon 2b, and the treatment group was treated with traditional Chinese medicine decoction on the basis of the control group. The clinical efficacy and life quality were observed. At the same time, the changes of immune function before and after treatment were compared.
After one course of treatment, the effective rate and clinical benefit rate of the treatment group were higher than those of the control group. The Karnofsky score in the treatment group was better than that in the control group. In improving the immune function, the treatment group was better than the control group in increasing CD3+ and CD4+ and reducing CD8+.
Traditional Chinese medicine decoction combined with recombinant human interferon 2b has a good effect on the treatment of RCC. It can not only improve the common clinical symptoms of patients but also improve the quality of life and cellular immune function of patients.
探讨中药汤剂联合重组人干扰素2b治疗肾细胞癌(RCC)的临床疗效。
将68例肾细胞癌患者分为对照组和治疗组(每组34例)。对照组采用重组人干扰素2b治疗,治疗组在对照组基础上加用中药汤剂治疗。观察临床疗效和生活质量。同时,比较治疗前后免疫功能的变化。
经过一个疗程的治疗,治疗组的有效率和临床受益率高于对照组。治疗组的卡氏评分优于对照组。在改善免疫功能方面,治疗组在增加CD3 +和CD4 +以及降低CD8 +方面优于对照组。
中药汤剂联合重组人干扰素2b治疗肾细胞癌效果良好。它不仅可以改善患者的常见临床症状,还可以提高患者的生活质量和细胞免疫功能。